Literature DB >> 10393001

Opioids in pain management.

H McQuay1.   

Abstract

Opioids are our most powerful analgesics, but politics, prejudice, and our continuing ignorance still impede optimum prescribing. Just over 100 years ago, opium poppies were still grown on the Cambridgeshire fens in the UK to provide oblivion for the working man and his family, but the brewing lobby argued on thin evidence that their potions were less dangerous. The restriction of opioid availability to protect society and the individual continues in many countries. In this review I focus on chronic and cancer pain, but many of the principles apply in acute pain. The justification for this focus is that patients with chronic pain may suffer longer and unnecessarily if we prescribe and legislate badly.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393001     DOI: 10.1016/S0140-6736(99)03528-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  68 in total

1.  Methadone: the question or the answer for US opioid therapy and pharmaco-economics?

Authors:  E D Dickerson
Journal:  Support Care Cancer       Date:  2001-11       Impact factor: 3.603

2.  Transdermal fentanyl for chronic low back pain.

Authors:  Seiji Ohtori; Gen Inoue; Sumihisa Orita; Yawara Eguchi; Nobuyasu Ochiai; Shunji Kishida; Masashi Takaso; Yasuchika Aoki; Kazuki Kuniyoshi; Junichi Nakamura; Tetsuhiro Ishikawa; Gen Arai; Masayuki Miyagi; Hiroto Kamoda; Miyako Suzuki; Tomoaki Toyone; Kazuhisa Takahashi
Journal:  Yonsei Med J       Date:  2012-07-01       Impact factor: 2.759

Review 3.  Mu-opioid receptor desensitization: is morphine different?

Authors:  Mark Connor; Peregrine B Osborne; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

4.  An anthology from Naunyn-Schmiedeberg's archives of pharmacology.

Authors:  Martin Michaelis; Bernward Schölkens; Karl Rudolphi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-02-20       Impact factor: 3.000

Review 5.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

6.  Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Authors:  Liting Deng; Josée Guindon; Benjamin L Cornett; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Biol Psychiatry       Date:  2014-04-25       Impact factor: 13.382

7.  Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.

Authors:  Jai Shankar K Yadlapalli; Benjamin M Ford; Amit Ketkar; Anqi Wan; Narasimha R Penthala; Robert L Eoff; Paul L Prather; Maxim Dobretsov; Peter A Crooks
Journal:  Pharmacol Res       Date:  2016-09-13       Impact factor: 7.658

8.  Spinal mediators that may contribute selectively to antinociceptive tolerance but not other effects of morphine as revealed by deletion of GluR5.

Authors:  A M Gregus; C N Inra; T P Giordano; A C S Costa; A M Rajadhyaksha; C E Inturrisi
Journal:  Neuroscience       Date:  2010-03-29       Impact factor: 3.590

9.  Molecular modelling and QSAR analysis of some structurally diverse N-type calcium channel blockers.

Authors:  Jignesh Mungalpara; Ashish Pandey; Vaibhav Jain; C Gopi Mohan
Journal:  J Mol Model       Date:  2009-10-04       Impact factor: 1.810

Review 10.  Opioids for low back pain.

Authors:  Richard A Deyo; Michael Von Korff; David Duhrkoop
Journal:  BMJ       Date:  2015-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.